Navigation Links
Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
Date:10/24/2008

DRS. PATRICIA BERG AND ARNOLD SCHWARTZ LED TEAM, Article in Modern Pathology set for print publication January 2009

BERG HAD ALSO DISCOVERED SAME GENE'S ACTIVATION IN MAJORITY OF BREAST CANCER CASES

WASHINGTON, Oct. 24 /PRNewswire-USNewswire/ -- A gene has been found activated in 70% of prostate cancer tumors, the same gene that has been discovered activated in a majority of breast cancer cases, report scientists at the George Washington University Medical Center led by Dr. Patricia Berg, who discovered and cloned the gene, and Dr. Arnold Schwartz. Berg is Professor of Molecular Biology and Biochemistry and directs a laboratory at George Washington University Medical Center in Washington, DC, and Schwartz is Professor of Pathology and practicing clinician at GWUMC.

In the January, 2009 print issue of Modern Pathology, a journal of the Nature Publishing Group, the team of researchers led by Berg and Schwartz will report that "Significant BP1 immunoreactivity was identified in approximately 70% of prostatic adenocarcinomas, whether the analysis was performed on tissue sections (50 cases) or tissue microarray platforms (123 cases)." The findings compare to "less than 5%" BP1 activity in normal cells. The researchers conclude that "These findings suggest that BP1 is an important upstream factor in the carcinogenic pathway of prostate cancer and that the expression of BP1 may reflect or directly contribute to tumor progression and/or invasion."

In addition to Berg and Schwartz, the team of authors includes Drs. Yan-Gao Man, Department of Gynecologic and Breast Pathology, The Armed Forces Institute of Pathology, Washington DC; M Katayoon Rezaei, Department of Pathology, The George Washington University Medical Center, Washington DC; and Samuel J Simmens, Department of Biostatistics, The George Washington University Medical Center, Washington DC.

Berg had previously published and reported, and the authors cite in the current article, that BP1 is activated in a majority of breast cancer (80%) and acute myeloid leukemia (63%) cases. The authors say, "Our current and past findings suggest that BP1 may be an important regulatory factor in the oncogenic pathway of several malignancies including prostate cancer." Berg stated today, "BP1 is a new, potentially significant target for therapy. It could be an important new diagnostic marker for prostate cancer and the other cancers in which it is expressed."

Prostate cancer is the leading cancer among men. The National Cancer Institute estimates 186,320 new cases and 28,660 deaths from prostate cancer in the U.S. in 2008.

The article is titled, "BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia." The article is also available as "advance online publication" (Citation: Modern Pathology advance online publication 17 October 2008; doi: 10.1038/modpathol.2008.168).

Link to abstract: http://www.nature.com/doifinder/10.1038/modpathol.2008.168.

CONTACT: Dr. Berg/GWUMC: Robert Weiner Associates, +1-301-283-0821, +1-202-329-1700, Modern Pathology: Marsha Cline, +1-317-274-2476


'/>"/>
SOURCE Dr. Patricia Berg of GWUMC/Robert Weiner Associates
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Research Foundation Achieves Milestone in Fight Against Cancer
2. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
3. New Genes Found for Inflammatory Bowel Disease in Children
4. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
5. Gene That Causes Childhood Cancer Neuroblastoma Is Found
6. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
7. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
10. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
11. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
(Date:4/27/2016)... MARLBOROUGH, Mass., April 27, 2016  Hologic, Inc. ... Company,s financial results for the fiscal second quarter ... share (EPS) of $0.24 increased 41.2%, and non-GAAP ... $693.3 million increased 5.8% on a reported basis, ... "We posted another good quarter, highlighted ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... This week Omega Institute, a ... guest season which runs through October. Omega is offering a record 370 in-person workshops ... “There has never been such widespread interest in or need for the knowledge and ...
(Date:5/2/2016)... ... 02, 2016 , ... Dr. Rassouli, dentist in Orange County, CA ... the research, which was published in the “Journal of the American Geriatrics Society,” more ... million Americans have Alzheimer’s disease. The study found that dental problems may increase the ...
(Date:5/2/2016)... RICHEY, Fla. (PRWEB) , ... ... ... and medical researchers report that many commonly used prescription medications, including anxiolytics, ... (1). To mitigate these risks, Novus Medical Detox Center —a leading ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... (AAC) event, will be held at the Bellagio Hotel in Las Vegas, NV ... Social Work (NASW) will be co-hosting the event. , This year’s conference will ...
(Date:5/2/2016)... ... May 02, 2016 , ... Consultative health care market research ... Callandrillo and Duane Reed, VP of business development of AJMC Strategic Solutions, will ... Group (PBIRG) General Meeting from May 15-17 at the Boca Raton Resort ...
Breaking Medicine News(10 mins):